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Abstract
Objective: To model the effects of demographic change under various scenarios of possible future treatment develop-
ments in ALS. Methods: Patients diagnosed with ALS at the King’s College Hospital Motor Nerve Clinic between 2004
and 2017, and living within the London boroughs of Lambeth, Southwark, and Lewisham (LSL), were included as inci-
dent cases. We also ascertained incident cases from the Canterbury region over the same period. Future incidence of
ALS was estimated by applying the calculated age- and sex-specific incidence rates to the UK population projections
from 2020 to 2116. The number of prevalent cases for each future year was estimated based on an established method.
Assuming constant incidence, we modelled four possible future prevalence scenarios by altering the median disease dur-
ation for varying subsets of the population, to represent the impact of new treatments. Results: The total number of peo-
ple newly diagnosed with ALS per year in the UK is projected to rise from a baseline of 1415 UK cases in 2010 to 1701
in 2020 and 2635 in 2116. Overall prevalence of ALS was predicted to increase from 8.58 per 100,000 persons in 2020
to 9.67 per 100,000 persons in 2116. Halting disease progression in patients with C9orf72 mutations would yield the
greatest impact of the modelled treatment scenarios, increasing prevalence in the year 2066 from a baseline of 9.50 per
100,000 persons to 15.68 per 100,000 persons. Conclusions: Future developments in treatment would combine with the
effects of demographic change to result in more people living longer with ALS.
Keywords: Epidemiology, models, survival, SOD1, therapy, genetics
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly
progressive neurodegenerative disease of motor
neurons leading to wasting, paralysis, and eventual
death from respiratory failure within 3 to 5 years.
The annual incidence is approximately 2 per
100,000 person-years in European (1) and US
populations (2). These incidence rates have
remained relatively stable over time (3). The life-
time risk is as high as 1 in 300 (4) with disease
burden increasing with age.
Demographic change poses challenges for care
provision and resourcing. Across developed and
developing countries, the proportion of people in
older age groups is predicted to increase signifi-
cantly over the coming decades (5), secondary to
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decreasing mortality and declining fertility. The
number of people aged 60 and over is expected to
double globally from 841 million in 2013 to more
than 2 billion in 2050, with a projected 69% global
increase in the number of ALS cases worldwide by
2040 (6).
A counterpoint to the challenge of future popula-
tion change is the hope offered by the possible devel-
opment of new ALS treatments to slow progression
and prolong survival for some or all patients. While
there is not yet such a treatment, significant survival
improvement might be expected in coming decades.
For example, randomized controlled trial evidence
shows that Riluzole can improve 12-month survival
by about 35% (7), and lithium may improve the sur-
vival of a genetic subgroup (8). Edaravone, though
not licensed in the UK, has been shown to slow
functional decline in ALS for a subgroup of patients
(9). Targeted gene therapy approaches are in devel-
opment (10), and future treatments may slow or
halt the progress of disease, resulting in a larger
prevalent cohort of people with ALS.
Population change and its interaction with the
effects of treatments have major implications for a
healthcare and societal system with limited resourc-
ing and many competing demands. We therefore
modelled the effects of demographic changes under
various scenarios of treatment outcomes in ALS.
Materials and methods
Incidence estimates
Patients diagnosed with ALS at the King’s College
Hospital Motor Nerve Clinic between 1 January
2004 and 31 December 2017, and living within
the London boroughs of Lambeth, Southwark,
and Lewisham (LSL), were included as incident
cases. These three south London boroughs were
selected because they comprise the primary catch-
ment for the centre, therefore ensuring good case
ascertainment. Patients with all subtypes of ALS
and all El Escorial diagnostic certainty categories
(as assigned at first presentation to the clinic) were
included. For patient confidentiality, postcode data
was only available to the level of postcode sector (a
geographical area containing approximately 3000
households), which cuts across borough boundaries,
and so incident cases were weighted according to
the proportion of the patient’s postcode sector that
fell within one of the three relevant boroughs.
Patients were grouped by sex and age accord-
ing to age at diagnosis in 5-year age bands from
15 years upwards, with an open-ended cohort for
those aged 90 years and above. In the event of no
cases within any particular category, we substituted
0.5 to allow extrapolation to future projections.
Crude age- and sex-specific incidence rates were
calculated using age- and sex-specific mid-2010
population estimates for the relevant boroughs as
the denominator from Office of National Statistics
(ONS) census data. Confidence intervals for crude
rates were calculated using the exact method for
Poisson intervals (11). These rates were standar-
dized to the UK population structure (mid-2010
estimate) (12) using the direct standardization
method. Confidence intervals for the overall age-
and sex-adjusted incidence rates were calculated at
the 95% level using an approximation of the stand-
ard error for a binomial proportion (13).
To provide a comparison and to increase our
total sample size, incident cases from the Canterbury
region arising over the same period (2004–2017)
were ascertained from the SEALS register (14)
which captures case referrals to the region’s motor
neuron disease specialist nursing service. Because
this service accepts referrals by postcode criteria, this
sample was defined by postcode sector rather than
by borough. Crude age- and sex-specific incidence
rates were calculated using age- and sex-specific
mid-2011 population data for the relevant postcode
sectors as the denominator (15). Denominator esti-
mates from 2011 were used (rather than 2010 as for
the London data) because this was a UK census
year for which postcode-level (rather than borough
level) statistics were available. Age- and sex-specific
incidence rates were standardized to the UK popula-
tion structure (mid-2011 population estimate) (16)
using the direct standardization method. Otherwise,
the sample data were processed and analyzed in the
same way as the London sample. To compare the
two regional age-standardized rates, the standardized
rate ratio (17) was calculated. Data from the
London boroughs and the Canterbury region were
pooled to provide incidence estimates from a larger
sample size incorporating urban, suburban, and rural
populations.
Prevalence estimates
Point prevalence was estimated at 30 June 2010
for the London boroughs, and 27 March 2011 for
the Canterbury region, based on date of availabil-
ity of population estimates for the different sam-
ples. Survival data were collected from hospital
and national case records. Prevalent cases were
included if diagnosis occurred any time after 1
January 1994. Confidence intervals (95%) for
point prevalence estimates were calculated by
Wilson’s method for calculating confidence inter-
vals for a proportion using OpenEpi software
(Emory University, Atlanta, GA, USA) (18).
Future projections
The effects of future population change on the
number of incident cases of ALS were estimated
by applying the calculated age- and sex-specific
incidence rates generated from the pooled dataset
to the main UK population projection (19) for
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each single year from 2020 to 2116, with popula-
tion counts for each single year of age summed to
correspond to our age cohorts. This generated an
estimate of the number of incident cases per future
year, by sex and age cohort.
Prevalence modelling
To estimate the number of prevalent cases in future
years, we used an established method (6). The
number of cases per year was estimated based on
the product of calculated age- and sex-specific inci-
dence rates, the age- and sex-specific future popula-
tion estimates taken from the main UK population
projection described above, and the median disease
duration. To generate estimates of median disease
duration we performed a Kaplan Meier survival ana-
lysis using data from the whole of the SEALS
Register (14). Cases were censored at death or at
last recorded follow up date, with median survival
(in months) calculated from date of symptom onset
to the censor/event date. Cases were grouped into
three age cohorts—under 40 years, 41–79 years and
80 years and over—based on findings of a previous
review of age as a prognostic factor in ALS (20).
Assuming constant incidence, we modelled
four different future prevalence scenarios to reflect
possible developments in treatment.
1. A new Riluzole-equivalent drug that increases
median survival in all affected people by
3 months.
2. A new gene therapy for SOD1 gene mutation
that increases median survival in carriers by
50%. Based on estimates of 10% of people with
ALS having an ascertained family history, 20%
of which can be attributed to SOD1 mutation,
and 2% of sporadic cases being SOD1 mutation
carriers (21), 4% of the total population was
selected for this survival benefit.
3. A new gene therapy for C9orf72 gene mutation
that increases median survival in carriers by
50%. Ten percent (10%) of the total
population was selected for this survival
benefit, based on estimated overall frequency
of C9orf72 mutations in studies of familial and
sporadic ALS cases (22–24).
4. A new gene therapy for C9orf72 gene mutation
that halts progression of disease. Ten percent
(10%) of the total population was selected for
this survival benefit, and survival for this
subgroup was derived from average period life
expectancies published in ONS life tables, up
to the year 2066 (25).
Results
Incidence estimates: Lambeth, Southwark, and
Lewisham (LSL) data
There were 152 incident cases identified over the
relevant period. Of these, 72 (47.4%) were female.
One person with an unspecified lower motor neu-
ron syndrome was excluded. There were 133 peo-
ple diagnosed with typical ALS. Of these, 43 were
recorded as “Definite” ALS according to El
Escorial criteria, 40 “Probable”, 3 “Probable,
laboratory-supported”, and 14 “Possible”. Five
people with ALS classified under the now defunct
category of “Suspected” were included. There
were no data on El Escorial category in 28 cases.
There were 14 people with primary lateral sclerosis
(PLS), 3 with progressive muscular atrophy
(PMA) and 1 with a pure pseudobulbar palsy, all
of whom were included. After exclusions, and
including partial counts as described above, there
were 122.9 cases for the incidence calculation.
Figure 1 illustrates the incidence sample
characteristics.
The overall crude incidence rate was 1.29 per
100,000 (95% CI 1.07–1.53). The overall inci-
dence rate standardized to the 2010 UK popula-
tion was 2.10 per 100,000 (95% CI 1.97–2.22).
The age-standardized rate in males was 2.27 per
100,000 (95% CI 2.08–2.46) and in females 1.93
per 100,000 (95% CI 1.76–2.10). Age- and sex-
specific incidence rates are provided in the supple-
mentary material (Supplementary Table A).
Incidence estimates: Canterbury data
There were 269 incident cases identified from
the register over the relevant period. One person
with a lower motor neuron syndrome was
excluded. Two people with Kennedy’s disease
were excluded. Of the remaining 266, 128
(48.1%) were female. ALS was diagnosed in 240
people, and there were 17 people with PLS and 9
with PMA. Of the 240 people with typical ALS,
41 were recorded as “Definite” according to El
Escorial criteria, 89 “Probable”, 18 “Probable,
laboratory-supported”, and 38 “Possible”. Five
people were classified under the now defunct cat-
egory of “Suspected”. There were no data on El
Escorial category in 49. Two were excluded due to
missing age data, leaving 264 in the final incidence
calculation. Figure 2 illustrates the incidence sam-
ple characteristics.
The overall crude incidence rate was 3.61 per
100,000 person-years (95% CI 3.19–4.07). The
overall incidence rate standardized to the 2011
UK population was 3.25 per 100,000 person-years
(95% CI 3.09–3.40). The age-standardized rate
was 3.51 per 100,000 person-years for males (95%
CI 2.38–3.74) and 3.01 per 100,000 person-years
for females (95% CI 2.80–3.21). Age- and sex-spe-
cific incidence rates are provided in the supple-
mentary material (Supplementary Table B). The
standardized rate ratio of the Canterbury and LSL
overall age-standardized rates was 1.55 (95% CI 1.
43–1.67).
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Pooled incidence data
When the data for the two regions were pooled,
the overall crude incidence rate was 2.27 per
100,000 person-years (95% CI 2.04–2.50). The
overall incidence rate standardized to the 2010
UK population was 2.74 per 100,000 person-years
(95% CI 2.59–2.88). The age-standardized rate in
males was 2.96 per 100,000 person-years (95% CI
2.74–3.17) and in females 2.53 per 100,000 per-
son-years (95% CI 2.34–2.72). Age- and sex-spe-
cific incidence rates are provided in the
supplementary material (Supplementary Table C).
Comparative rates are summarized in Table 1.
Prevalence estimates
Using the LSL dataset, there were 37 people iden-
tified as living with ALS at the relevant date. The
point prevalence estimate was 5.29 per 100,000
persons (95% CI 3.84–7.30). Using the
Canterbury dataset, there were 44 people identi-
fied as living with ALS at the relevant date. The
Excluded: 1 case of 
unspecified lower 
motor neuron syndrome  
152 incident cases identified: 
     - 72 females 
     - 80 males 
133 cases of typical ALS;  
El Escorial criteria (n): 
- Definite (43) 
- Probable (40) 
- Probable, laboratory-supported (3) 
- Possible (14) 
- Suspected (5) 
- Unassigned (28) 
18 others (n): 
- Primary Lateral Sclerosis  
(PLS) (14) 
- Progressive Muscular Atrophy 
(PMA) (3) 
- Pure Pseudobulbar Palsy  
(PBP) (1) 
After weighting of cases: 
122.9 cases for incidence 
calculation 
n=151
Figure 1. Flowchart of incidence sample characteristics: Lambeth, Southwark, and Lewisham (LSL) data.
Excluded (n): 
- Lower motor neuron 
syndrome  (1) 
- Kennedy’s syndrome (2) 
269 incident cases identified: 
     - 129 females 
     - 140 males 
240 cases of typical ALS;  
El Escorial criteria (n): 
- Definite (41) 
- Probable (89) 
- Probable, laboratory-supported (18) 
- Possible (38) 
- Suspected (5) 
- Unassigned (49) 
26 others (n): 
- Primary Lateral Sclerosis  
(PLS) (17) 
- Progressive Muscular Atrophy 
(PMA) (9) 
264 cases for incidence 
calculation 
Excluded (n): 
- Missing age data 
(2)
Figure 2. Flowchart of incidence sample characteristics: Canterbury data.
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point prevalence estimate was 8.30 per 100,000
persons (95% CI 6.19–11.15).
Future projections
Figure 3 illustrates the projected trend of new
cases arising per year, by sex and by age group for
each sex. The total number of people newly diag-
nosed with ALS per year in the UK is projected to
rise over the coming decades, from a baseline of
1415 UK cases in 2010 to 1701 in 2020 and 2635
in 2116. For males, the projected increase in new
cases was from 743 in 2010 to 1540 in 2116, with
population increases in the highest age cohort
(over 90 years) contributing significantly to this
rise. For females, the projected increase was from
672 new cases in 2010 to 1165 new cases in 2116.
Prevalence modelling—survival analysis
A total of 953 cases were identified in the SEALS
register, 434 of whom (45.4%) were female.
Diagnoses other than ALS were excluded (three
people with Kennedy’s syndrome, one with mul-
tiple sclerosis, one with a lower motor neuron syn-
drome, and one other). There were 803 cases of
ALS with defined phenotypes (e.g. flail arm, flail
leg, with FTD, and bulbar palsy); 50 people where
no specific ALS phenotype was listed were also
included. Two hundred had El Escorial “Definite”
ALS, 355 “Probable”, 43 “Probable, laboratory-
supported”, and 107 “Possible”. Twenty were
classified under the now defunct El Escorial cat-
egory of “Suspected”. There were no data on El
Escorial category in 128.
There were 59 people with PLS, 29 with PMA,
and 6 with a pure pseudobulbar palsy, all of whom
were included. Those without a date of onset were
excluded (n¼ 43), as well as those with no age at
diagnosis (n¼ 2), leaving 902 for survival analysis.
Figure 4 illustrates the incidence sample character-
istics. Median survival estimates are displayed in
Table 2.
At baseline, using the pooled incidence rates
and the above survival estimates, overall prevalence
of ALS was predicted to increase from 8.58 per
100,000 persons in 2020 to 9.67 per 100,000 per-
sons in 2116. Prevalence estimates resulting from
other scenarios are displayed in Table 3 and
illustrated individually in comparison to the base-
line scenario in Figure 5.
Discussion
Our study pooled data from two regions of south-
east England to generate robust incidence rate esti-
mates for ALS in the UK, and used these to pre-
dict the effects of future demographic and
scientific change on the numbers of people living
with ALS in the UK up to the year 2116.
Demographic change will almost double the num-
ber of people newly diagnosed with ALS each
year, from a baseline of 1415 cases in 2010 to
2635 cases in 2116. In combination with this,
future developments in treatment for ALS can be
predicted to alter the prevalence of the disease by
prolonging survival to varying degrees. Halting dis-
ease progression entirely in patients who are
C9orf72 mutation carriers would yield the greatest
impact of the scenarios we modelled, increasing
prevalence in 2066 from a predicted baseline of
9.50 per 100,000 persons to 15.68 per 100,000
persons. The discovery of a new drug treatment
equivalent to the only currently licensed drug ther-
apy in the UK (Riluzole) would generate the next
greatest impact, with an estimated ALS prevalence
of 10.56 per 100,000 in 2116 compared to a base-
line of 9.56 per 100,000.
This study represents an updating of previously
published ALS epidemiological research, including
data from the same regions over different study
periods. For example, an earlier study from our
research group (4) presented incidence data from
the LSL boroughs from 1997 to 2004, and
reported a crude incidence rate of 1.20 cases per
100,000 person-years, which is similar to our
crude incidence rate of 1.29 cases per 100,000
person-years. It was adjusted to the England and
Wales population, rather than the whole of the
UK, so comparisons of overall age- and sex-
adjusted rates are not possible. Using current inci-
dence estimates to make future ALS prevalence
predictions is a technique deployed previously (6)
to make global predictions for the year 2040. In
relation to Europe, the earlier study predicted that
the number of individuals living with ALS would
increase by 20% between the years 2015 and
2040. Our model predicts a 30% increase in UK
Table 1. Summary of crude and adjusted incidence rates for Lambeth, Southwark, and Lewisham (LSLS) data, Canterbury region
data, and pooled data, 2004–2017.
LSL data Canterbury data Pooled data
Crude incidence rate (per 100,000 per year) (95% CI) 1.29 (1.07–1.53) 3.61 (3.19–4.07) 2.27 (2.04–2.50)
Male age-adjusted incidence rate 2.27 (2.08–2.46) 3.51 (2.38–3.74) 2.96 (2.74–3.17)
Female age-adjusted incidence rate 1.93 (1.76–2.10) 3.01 (2.80–3.21) 2.53 (2.34–2.72)
Overall age- and gender-adjusted incidence rate 2.10 (1.97–2.22) 3.25 (3.09–3.40) 2.74 (2.59–2.88)
Number of cases 1084 1695 1415
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Figure 3. Predicted number of new cases of ALS arising in UK per year, by sex and by age group for each sex, 2020–2116. This is the
illustration of future incidence projections. (a) Number of new UK cases arising per future year, by sex. Male incidence remains higher
than female incidence, with a slight increase in the number of male cases arising in later years due to projected improvements in male
life expectancy. (b) Number of new UK male cases arising per future year, by age cohort. Note the particularly steep rise in annual
incidence rate for males in the 90þ age cohort; this is attributable to projected improvements in life expectancy for males resulting in
increasingly large numbers of males reaching this age cohort, combined with a relatively high age-specific incidence rate in our sample
(7.56 male cases per 100,000 persons compared to 1.99 female cases per 100,000 persons in this age cohort). (c) Number of new UK
female cases arising per future year, by age cohort. This suggests an increase in the number of cases arising per year in future,
particularly among the older age cohorts.
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Exclusions (n): 
- Lower motor neuron 
syndrome  (1) 
- Kennedy’s syndrome 
(3) 
- Multiple sclerosis (1) 
- Other (1)
953 cases identified: 
     - 434 females 
     - 519 males 
853 cases of typical ALS;  
El Escorial criteria (n): 
- Definite (200) 
- Probable (355) 
- Probable, laboratory-supported (43) 
- Possible (107) 
- Suspected (20) 
- Unassigned (128) 
94 others (n): 
- Primary Lateral Sclerosis  
(PLS) (59) 
- Progressive Muscular Atrophy 
(PMA) (29) 
- Pure Pseudobulbar Palsy (6) 
902 cases for survival analysis 
Excluded (n): 
- Missing age data (2) 
- Missing date of onset 
(43) 
Figure 4. Flowchart of survival analysis sample characteristics.
Table 2. Results of Kaplan-Meier survival analysis: mean and median survival estimates (months) by age cohort.
Means and medians for survival time
Overall
Age cohort
Mean Median
Estimate Std. error
95% Confidence interval
Estimate Std. error
95% Confidence interval
Lower bound Upper bound Lower bound Upper bound
<40 67.61 10.13 47.75 87.47 56.00 26.01 5.01 106.99
40–79 63.09 4.59 54.09 72.08 35.00 1.37 32.32 37.68
80þ 42.82 7.38 28.35 57.29 26.00 3.31 19.51 32.49
Overall 61.46 3.94 53.73 69.18 34.00 1.06 31.92 36.08
Table 3. Summary of prevalence estimates for males, females, and both at baseline and for each modeled scenario, showing first and
last year of available data.
Male prevalence
per 100,000
Female prevalence
per 100,000
Overall prevalence
per 100,000
2020 2116 2020 2116 2020 2116
Baseline 9.34 11.12 7.88 8.65 8.58 9.67
Scenario 1
(overall 3-month survival increase)
10.16 12.15 8.57 9.44 9.34 10.56
Scenario 2
(50% survival increase in SOD1 mutation carriers)
9.52 11.34 8.04 8.82 8.75 9.87
Scenario 3
(50% survival increase in C9orf72 mutation carriers)
9.80 11.68 8.27 9.08 9.01 10.16
2020 2066 2020 2066 2020 2066
Baseline 9.34 10.55 7.88 8.67 8.58 9.50
Scenario 4
(halt progression in C9orf72 mutation carriers)a
14.55 17.24 12.44 14.36 13.49 15.68
aScenario 4 comparisons are shown for the years 2020 and 2066, which is the last year for which projected life expectancy data
is available.
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cases over approximately the same period
(2016–2040), based on more detailed survival esti-
mates (by age group and by sex), as well as locally
derived age- and sex-specific incidence rates. The
average direct medical cost for someone with ALS
is estimated at US$3436 per month (26). The
increase in prevalence over our whole study period
(2020–2116) would therefore be predicted to add
at least an additional US$95m to current
healthcare costs in the UK. Our study goes further
in attempting to model the impact of possible (and
plausible) future developments in treatment, all of
which would combine with the effect of population
increase to result in more people living longer with
ALS. This effect is likely to be generalizable to
other neurodegenerative diseases, which are also
predicted to become more prevalent in an aging
population e.g. Alzheimer’s dementia (27).
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Figure 5. Future prevalence estimates for each modelled scenario compared to baseline. (a) Baseline compared to a treatment that
prolongs survival in all cases by three months. (b) Baseline compared to a treatment that prolongs median survival by 50% in the
subgroup of patients with SOD1 mutation. (c) Baseline compared to a treatment that prolongs median survival by 50% in the subgroup
of patients with C9orf72 mutation. (d) Baseline compared to a treatment that halts disease progression in the subgroup of patients with
C9orf72 mutation, so that the life expectancy of these patients reverts to that predicted for their age, sex, and year cohort. This scenario
generates the most significant difference in disease prevalence compared to baseline. Note that the range of the x-axis is different for (d)
(2020–2066) compared to (a–c) (2020–2116) due to more limited availability of projected life expectancy data. Note that for all parts
of Figure 5, the y-axis lower limit is eight (prevalent cases per 100,000 persons), not 0, for better illustration of the range of
prevalence estimates.
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Our study also found significantly different
incident rates between two parts of south-east
England, an inner city area (LSL) and a more
mixed suburban/rural region (Canterbury), with
higher rates estimated from the Canterbury region
data. This is likely to derive in part from the differ-
ent demographic structures of the two areas, with
21% of the Canterbury population aged over 65,
compared to just 9% for the LSL population. Our
inner city estimate is nonetheless higher than a
previous estimate using the same sample area (4),
which reported an overall adjusted incidence rate
of 1.66—though this was standardized to an
England and Wales population rather than to the
whole UK as in our study. The pooled data
yielded a crude incidence rate (2.27 per 100,000)
comparable to that quoted in European register
studies (e.g. 2.16 per 100,000 in (1)), with our
slightly higher rate possibly explained by our inclu-
sion of a lower motor neuron predominant and
upper motor neuron predominant forms of ALS
rather than only typical ALS. This broader focus is
likely a contributing factor to our higher point
prevalence estimates compared to European median
estimates (28), as we include subtypes like PLS
that tend to have considerably longer median sur-
vival times than ALS (29). It could be argued that
our decision to include these upper or lower motor
neuron predominant forms, albeit in their relatively
small absolute case numbers, dilutes the ALS epi-
demiological dataset and limits comparability with
other studies. However, this enables us to better
capture cases where there may be some doubt
about the precise motor neuron disease diagnosis
(30), as well as better reflect the likely future
demands on motor nerve clinic services overall.
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Figure 5. Continued
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Similarly, current treatments under exploration
tend to focus on potential targets within the known
pathophysiological models of ALS (10) therefore
our higher prevalence estimates under the different
treatment scenarios (compared to baseline) may be
overestimates, given that we have included non-
typical ALS cases in the baseline incidence calcula-
tions. We have made some assumptions about the
different treatment scenarios, which were selected
based on biological plausibility and some early
findings from animal models; for example, a trial
of antisense oligonucleotide therapy in transgenic
(SOD1-G93A) rats and resulted in reduced
mutated SOD1 as well as extended survival (31);
our selection of 50% survival extensions in two of
our modelled scenarios remains somewhat arbi-
trary, and could be refined in further studies to
reflect ongoing work in animal models and results
from early human clinical trials.
This study’s findings may also be limited by
the assumptions we have made about population
changes. We used the Office for National Statistics
main population projection model, which makes
certain assumptions about aging, migration and
other factors. There is a developing body of evi-
dence to suggest that the incidence and prevalence
of ALS may vary with ethnicity and ancestry (32),
therefore it is plausible that future changes in eth-
nic diversity in the UK could affect our projec-
tions. Alternative ONS projections that assume,
for example, higher levels of inward migration,
could be used to repeat the analyses undertaken in
this study. It is also possible that there are environ-
mental modifiers of ALS epidemiology that are not
considered in our study, such as birth cohort
effects restricted to particular groups (33).
We did not model any scenarios wherein dis-
ease onset could be prevented altogether within
any particular sub-group of ALS patients; this
could provide an interesting comparison to the
scenarios modelled here, all of which predict
increased future disease prevalence, but is cur-
rently unlikely given the frequency of ALS in the
population and the consequent statistical challenge
in developing an effective screening test. Another
recommendation for further work in this field is to
continue the collection and refinement of robust
epidemiological data about ALS, which should be
promoted by the emergence of a national ALS
patient register as well as use of capture–recapture
techniques to improve the reliability of incidence
and prevalence estimates.
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